tandutinib-resistant FLT3 mutants

Stable Identifier
R-HSA-9702636
Type
Pathway
Species
Homo sapiens
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
tandutinib-resistant FLT3 mutants
Click the image above or here to open this pathway in the Pathway Browser
Tandutinib, also known as MLN519, is a type II tyrosine kinase inhibitor with activity against FLT3 (Clark et al, 2004; reviewed in Staudt et al, 2018; Daver et al, 2019). This pathway describes FLT3 mutants that are resistant to tandutinib-mediated inhibition.
Literature References
PubMed ID Title Journal Year
15256420 Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518

Clark, JJ, Cools, J, Curley, DP, Yu, JC, Lokker, NA, Giese, NA, Gilliland, DG

Blood 2004
30651634 Targeting FLT3 mutations in AML: review of current knowledge and evidence

Daver, N, Schlenk, RF, Russell, NH, Levis, MJ

Leukemia 2019
30332834 Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance

Staudt, D, Murray, HC, McLachlan, T, Alvaro, F, Enjeti, AK, Verrills, NM, Dun, MD

Int J Mol Sci 2018
Participants
Events
Participates
as an event of
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Cross References
Mondo
Authored
Rothfels, K  (2020-11-06)
Reviewed
Kazi, JU  (2020-11-06)
Created
Rothfels, K  (2020-10-01)
Cite Us!